Stockscreener 앱 받기
13.07
1.32%
0.17
Capricor Therapeutics Inc 주식(CAPR)의 최신 뉴스
(CAPR) Trading Advice - Stock Traders Daily
Capricor Therapeutics (CAPR) Stock Dips Amid Biotech Sector Decl - GuruFocus.com
Capricor Therapeutics Inc (NASDAQ:CAPR) Short Interest Update - MarketBeat
Capricor Therapeutics (NASDAQ:CAPR) Trading Down 5.3%Here's Why - MarketBeat
Capricor Therapeutics (CAPR) Stock Drops Amid Volatile Biotech Sector - GuruFocus.com
High Growth Tech Stocks To Watch In December 2024 - Simply Wall St
RFK Jr. could prove a surprise boon for stem-cell stocks with pivotal year ahead - MarketWatch
Some Capricor Therapeutics, Inc. (NASDAQ:CAPR) Shareholders Look For Exit As Shares Take 27% Pounding - Simply Wall St
(CAPR) Pivots Trading Plans and Risk Controls - Stock Traders Daily
250,204 Shares in Capricor Therapeutics Inc (NASDAQ:CAPR) Purchased by Point72 Asset Management L.P. - MarketBeat
Deramiocel's Promise Brightens Capricor's Outlook, With Strings Attached (NASDAQ:CAPR) - Seeking Alpha
Capricor: Additional Deramiocel Data Bodes Well For Initiated Rolling BLA Submission - Seeking Alpha
Jones Trading keeps $40 target on Capricor Therapeutics By Investing.com - Investing.com UK
Piper Sandler maintains $35 target on Capricor shares By Investing.com - Investing.com Canada
Capricor Therapeutics (CAPR) Stock Surges Amid Positive Analyst Ratings - GuruFocus.com
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
Capricor Therapeutics to Present at Upcoming Investor Conferences - The Manila Times
Capricor Therapeutics to Present at Major Healthcare Conferences in December | CAPR Stock News - StockTitan
Walmart Inc (WMT-N) QuotePress Release - The Globe and Mail
Capricor Therapeutics Inc (NASDAQ:CAPR) Receives $34.50 Average Price Target from Analysts - MarketBeat
Capricor Therapeutics (CAPR) Sees Stock Surge Amid Positive Anal - GuruFocus.com
Pork Cutout (KMG25) Quote - The Globe and Mail
Capricor Therapeutics Executes Collaboration Agreement and Exclusive License Option with Janssen Biotech - Marketscreener.com
Capricor wins key EU designations for the lead asset - MSN
Capricor stock on watch after key EU designations (CAPR:NASDAQ) - Seeking Alpha
Capricor Therapeutics Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines Agency - The Manila Times
(CAPR) Proactive Strategies - Stock Traders Daily
Capricor Therapeutics shares rated Buy by Jones Trading, boosted by DMD-CM therapy - Investing.com Canada
What is HC Wainwright's Estimate for CAPR FY2024 Earnings? - MarketBeat
KBW Bank Index (BKX) QuotePress Release - The Globe and Mail
Capricor Therapeutics Inc (NASDAQ:CAPR) Short Interest Down 14.6% in October - MarketBeat
Is Capricor Therapeutics (CAPR) the Best Multibagger Stock to Buy Heading into 2025? - Yahoo Finance
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q3 2024 Earnings Call Transcript - Insider Monkey
Capricor Therapeutics Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Capricor Therapeutics Inc (CAPR) Quarterly 10-Q Report - Quartzy
10 Best Multibagger Stocks To Buy Heading into 2025 - Insider Monkey
Earnings call: Capricor outlines deramiocel's path to market for DMD treatment - Investing.com Canada
Capricor Therapeutics (NASDAQ:CAPR) Trading 7.3% Higher on Analyst Upgrade - MarketBeat
Cantor Fitzgerald Issues Positive Forecast for Capricor Therapeutics (NASDAQ:CAPR) Stock Price - MarketBeat
Decoding 12 Analyst Evaluations For Capricor Therapeutics - Benzinga
Capricor Therapeutics (CAPR) Reports Q3 Loss, Misses Revenue Estimates - MSN
Capricor Therapeutics Advances with Strategic Expansions - TipRanks
Capricor: Q3 Earnings Snapshot - San Antonio Express-News
Capricor Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
Capricor Therapeutics earnings missed by $0.02, revenue fell short of estimates - Investing.com UK
2.88%
2.65%
자본화:
|
볼륨(24시간):